Journal of Enzyme Inhibition and Medicinal Chemistry

ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: informahealthcare.com/journals/ienz20

Antitubercular activity of novel substituted 4, 5-dihydro-1*H*-1-pyrazolylmethanethiones

Mohamed Ashraf Ali & Mohammad Shahar Yar

To cite this article: Mohamed Ashraf Ali & Mohammad Shahar Yar (2007) Antitubercular activity of novel substituted 4, 5-dihydro-1*H*-1-pyrazolylmethanethiones, Journal of Enzyme Inhibition and Medicinal Chemistry, 22:2, 183-189, DOI: 10.1080/14756360601072437

To link to this article: https://doi.org/10.1080/14756360601072437

Journal of Enzyme Inhibition and Medicinal Chemistry, April 2007; 22(2): 183–189

informa
healthcare

Antitubercular activity of novel substituted 4, 5-dihydro-1*H*-1-pyrazolylmethanethiones

MOHAMED ASHRAF ALI & MOHAMMAD SHAHAR YAR

Faculty of Pharmacy, Jamia Hamdard University, Department of Pharmaceutical Chemistry, Hamdard Nagar, New Delhi - 110062, India

(Received 1 June 2006; in final form 16 September 2006)

Abstract

A series of, anilino-5- (substituted) phenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione and 2-chloroanilino-5- (substituted) phenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione were synthesized by the reaction between hydrazine hydrate and the chalcones (3**a**–**k**) followed by condensation with the appropriate aryl isothiocyanate which yielded the N-substituted pyrazoline derivatives. These were tested for their *in-vitro* anti-mycobacterial activity against INH resistant *Mycobacterium tuberculosis* (INHR MTB) using the BACTEC 460 radiometric system. Compound 2-chloroanilino-5-(2,6-dichlorophenyl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1*H*-1-pyrazolyl-methanethione (**6i**) was found to be most active agent with a minimum inhibitory concentration of 0.96μg/mL.

Keywords: *Pyrazoline, isoniazid, isothiocyanate, INH resistant mycobacterium tuberculosis and antitubercular agent*

Introduction

Among infectious diseases, tuberculosis (TB) is the leading killer with over two million casualties annually worldwide. The WHO considers tuberculosis to be the most dangerous chronic communicable disease in the world [1]. The emergence of AIDS, decline of socio-economic standards and a reduced emphasis on tuberculosis control programs contribute to the disease's resurgence in industrialized countries [2]. Resistance of *Mycobacterium tuberculosis* strains to anti-mycobacterial agents is an increasing problem worldwide [3–5]. In spite of severe toxicity on repeated dosing of isoniazid (INH), it is still considered to be a first line drug for the chemotherapy of tuberculosis. Literature survey reveals pyrazoline derivatives are active against many mycobacteria [6–9]. The current work describes the synthesis of novel pyrazoline moieties with encouraging anti-mycobacterial activity against *M. tuberculosis* H_{37}Rv.

Materials

Chemicals were supplied by E.Merck (Germany) and S.D fine chemicals (India). Melting points were determined by open tube capillary method and are uncorrected. Purity of the compounds was checked on thin layer chromatography (TLC) plates (silica gel G) in the solvent system toluene-ethyl formate- formic acid (5:4:1) and benzene (CARE-CARCINOGENIC) -methanol (8:2) and the spots were located under iodine vapors or UV light. IR spectra were obtained on a Perkin-Elmer 1720 FT-IR spectrometer (KBr Pellets). ^{1}H NMR spectra were recorded or a Bruker AC 300 MHz spectrometer using TMS as internal standard in DMSO-d6.

Methods

Chemistry

*General method for the preparation of 1-(4-hydroxy-3-methyl-phenyl)-3- (substituted) phenyl-2-propen-1-ones (**3a–k**).* 4-Hydroxy-3-methyl acetophenone (1.5017 g, 0.01 mmol), appropriate aldehyde (0.01 mmol), were dissolved in ethanol and sodium hydroxide (30%, 5mL) with 10 ml of petroleum ether was stirred under room temperature for 4 h. The resulting solution was allowed to stand overnight then

Correspondence: M. S. Yar, Faculty of Pharmacy, Jamia Hamdard University, Department of Pharmaceutical Chemistry, Hamdard Nagar, New Delhi - 110062, India. Tel: 91 9899452373. Fax: 91 11 26059666. E-mail: yarmsy@rediffmail.com

ISSN 1475-6366 print/ISSN 1475-6374 online © 2007 Informa UK Ltd.
DOI: 10.1080/14756360601072437

poured into ice-cold water then neutralized with HCl. The solid which separated was filtered off dried and purified from ethanol.

*1-(4′-hydroxy-3′-methyl-phenyl)-3-(4″-methoxy phenyl)-2-propen-1-one (**3a**). IR: (KBr) cm*$^{-1}$ 3200(OH), 3040(CH), 1680(C═O); ^{1}H*–NMR (DMSO-d6) ppm*: 2.2(3H,s,CH_3), 3.9 (3H,s, OCH_3), 6.9–7.5(1H × 2,dd, —CH═CH), 7.7–8.2(7H,s, aromatic), 9.2 (1H,s, OH).

*1-(4′-hydroxy-3′-methyl-phenyl)-3- (4″-choloro phenyl)-2-propen-1-one (**3b**). IR: (KBr) cm*$^{-1}$ 3200(OH), 3040(CH), 1680(C═O), 772(C—Cl); ^{1}H*–NMR (DMSO-d6) ppm*: 2.2(3H,s, CH_3), 6.9–7.5(1H × 2, dd, —CH═CH), 7.7–8.2(7H,m, aromatic), 9.2 (1H,s, OH).

*1-(4′-hydroxy-3′-methyl-phenyl-3- (4″-dimethyl amino phenyl)-2-propen-1-one (**3c**). IR: (KBr) cm*$^{-1}$ 3200 (OH), 3040(CH), 1680(C═O); ^{1}H*–NMR (DMSO-d6) ppm*: 2.2(3H,s,CH_3), 3.9(6H,s, N (CH_3 × 2), 6.9–7.5(1H × 2,dd, —CH═CH), 7.7–8.2(7H,m, aromatic), 9.2 (1H,s, OH).

*1-(4′-hydroxy-3′-methyl-phenyl)-3- phenyl-2-propen-1-one (**3d**). IR: (KBr) cm*$^{-1}$ 3200(OH), 3040(CH), 1680(C═O); ^{1}H – NMR (*DMSO-d6*) *ppm*: 2.2(3H,s, CH_3), 6.9–7.5(1H × 2,dd, —CH═CH), 7.7–8.2 (8H,m, aromatic), 9.2 (1H,s, OH).

*1-(4-hydroxy-3-methyl-phenyl)-3- (3″,4″-dimethoxy phenyl)-2-propen-1-one (**3e**). IR: (KBr) cm*$^{-1}$ 3200 (OH), 3040(CH), 1680(C═O); ^{1}H*–NMR (DMSO-d6) ppm*: 2.2(3H,s, CH_3), 3.9(6H,s, OCH_3 × 2), 6.9–7.5(1H × 2,dd, —CH═CH), 7.7–8.2(6H,m, aromatic), 9.2 (1H,s, OH).

*General method for the preparation of 4-[5′-(substituted) phenyl -4,5-dihydro-1H-3-pyrazolyl]-2-methylphenols (**4a–k**).* Chalcone (3**a**–**k**) (0.01 mol) and ethanol (20mL) was mixed and hydrazine hydrate (99%) (0.02 mol, 0.1mL) was added dropwise. The reaction mixture was heated under reflux for 7 h, then cooled and poured onto crushed ice. The obtained solid was filtered and recrystalized from ethanol.

*4-[5-(4′-methoxyphenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4a**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1590(C═N), 1320(C—N)); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 3.4(3H,s,CH_3), 3.9(3H,s, OCH_3),4.24 (1H,s, CH), 5.52(1H,s, NH), 7.3–7.8 (7H,m, aromatic),9.5(1H,s, OH).

*4-[5-(4′-chlorophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4b**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1590(C═N), 1320(C—N), 770(C—Cl); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 3.4(3H,s,CH_3), 4.24 (1H,s, CH), 5.50(1H,s, NH),7.0–7.6(7H,m, aromatic), 9.5(1H,s, OH).

*4-[5-(4′-dimethylamonophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4c**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1580(C═N), 1324(C—N); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 2.9(3H × 2,s, $N(CH_3)_2$), 3.4(3H,s,CH_3), 4.24 (1H,s, CH), 5.52 (1H,s, NH), 7.4–8.0(7H,m, aromatic), 9.5(1H,s, OH).

*2-methyl-4-(5′-phenyl-4,5-dihydro-1H-3-pyrazolyl)-phenol (**4d**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1590(C═N), 1320(C—N); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 3.4(3H,s,CH_3), 5.54(1H,s, NH), 4.24 (1H,s, CH), 7.3–7.8(8H,m, aromatic), 9.5(1H,s, OH).

*4-[5-(3′,4′-dimethoxyphenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4e**). IR: (KBr, cm*$^{-1}$*)* 3310 (OH), 1590(C═N), 1320(C—N); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 3.4(3H,s, CH_3), 3.7(6H,s,2 × OCH_3), 7.0–7.8(6H,m,aromatic), 5.50 (1H,s,NH), 4.24 (1H, s,CH), 9.2(1H,s,OH).

*4-[5-(3′,4′,5′-trimethoxyphenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4f**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1596(C═N), 1320(C—N)); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 2.3(2H,s, CH_2), 3.4(3H,s, CH_3),3.6(9H,s,OCH_3), 4.24 (1H,s, CH), 5.48(1H,s, NH), 7.3–7.8(5H,m,aromatic),9.5(1H,s,OH).

*4-[5-(4′-fluorophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4g**). IR: (KBr, cm*$^{-1}$*)* 3312(OH), 1590(C═N), 1320(C—N), 700(C—F); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 9.4(1H,s, OH), 7.3–7.8(7H,m, aromatic), 5.42(1H,s,NH), 4.24 (1H,s, CH), 3.4 (3H,s,CH_3), 2.3(2H,s, CH_2).

*4-[5-(2′-chlorophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4h**). (KBr, cm*$^{-1}$*)* 3306(OH), 1586 (C═N), 1320(C—N), 774(C—Cl); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 9.5(1H,s, OH), 7.6–8.2(7H,m, aromatic), 5.50(1H,s, NH), 4.24 (1H,s, CH), 3.4 (3H,s,CH_3), 2.3(2H,s, CH_2).

*4-[5-(2′,6′-dichlorophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4i**). IR: (KBr, cm*$^{-1}$*)* 3317 (OH), 1594(C═N), 1320(C—N), 770(C—Cl); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 9.5(1H,s, OH), 7.3–7.8 (6H,m, aromatic), 5.54(1H,s, NH), 4.24 (1H,s, CH), 3.4(3H,s,CH_3), 2.3(2H,s, CH_2).

*4-[5-(3′-nitrophenyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4j**). IR: (KBr, cm*$^{-1}$*)* 3307(OH), 1590 (C═N), 1320(C—N); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 9.4(1H,s, OH), 7.8–8.4(7H,m, aromatic), 5.56 (1H,s, NH), 4.20 (1H,s, CH), 3.2(3H,s,CH_3), 2.7 (2H,s, CH_2).

*4-[5-(2′-furyl)-4,5-dihydro-1H-3-pyrazolyl]-2-methylphenol (**4k**). IR: (KBr, cm*$^{-1}$*)* 3317(OH), 1590(C═N), 1320(C—N); ^{1}H*–NMR (DMSO-*d_6*, ppm):* 7.3–7.8(3H,m, aromatic), 7.8–8.2(3H,m, furan), 5.52(1H,s, NH), 4.20 (1H,s, CH), 3.42(3H,s,CH_3), 2.3(2H,s, CH_2), 9.2(1H,s, OH).

*General method for the preparation of anilino-(substituted) phenyl 3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethiones (**5a–k**)*. To a solution of pyrazoline 4**a**–**k** (0.01 mol) in ethanol (20mL) was added phenyl isothiocyanate (1.50 mL, 0.01 mol) and the reaction mixture was refluxed for 4 h. The reaction mixture was cooled and then poured onto crushed ice. Then obtained solid was filtered, washed with water and purified from ethanol.

*anilino-5-(4- methoxy phenyl-3-(4-hydroxy-3-methyl-phenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5a**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3224(NH),1596(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.4(2H,s, CH_2), 2.7(3H,s, CH_3), 3.9(3H,s, OCH_3), 5.3 (1H,s, CH), 6.9–7.5(12H,m, aromatic), 9.4(1H,s, OH), 11.0(1H, s, NH); MS *m/z*: 418(M^{+1}); Cal/Ana[C (69.04) 69.05,H (5.55) 5.57,N (10.06) 10.04%]

*anilino-5-(4- chloro phenyl-3-(4-hydroxy-3-methyl-phenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5b**). IR: (KBr) cm*$^{-1}$ 3317(OH), 3220(NH),1590 (C═N), 1320(C—N), 1130 (C═S), 770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.7(6H,s, $2 \times CH_3$), 5.2 (1H,s, CH), 7.2–7.6(12H,m, aromatic), 9.5(1H,s, OH), 10.0(IH, s, NH); MS *m/z* 421(M^+); Cal/Ana[C (65.47) 65.45,H (4.78) 4.77,N (9.96) 9.96%]

*anilino-5-(4- dimethyl amino phenyl-3-(4-hydroxy-3-methylphenyl)-4, 5-dihydro-1H-1-pyrazolyl metha-nethione (**5c**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220 (NH),1590(C═N), 1320(C—N),1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.6(6H,s, CH_3), 3.3(6H,s, —$N(CH_3)_2$), 4.9 (1H,s, CH), 7.2–8.0 (12H,m, aromatic), 9.0(1H,s, OH), 10.0(IH, s, NH); MS *m/z*: 431(M^{+1}); Cal/Ana[C (69.74) 69.73,H (6.09) 6.03,N (13.01) 13.04%]

*anilino-5-(phenyl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5d**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH),1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.1(2H,s, CH_2), 2.9(3H,s,CH_3), 5.1 (1H,s, CH), 7.2–7.8 (13H,m, aromatic), 9.7(1H,s, OH), 10.0(IH, s, NH);MS *m/z*: 386(M^{-1}); Cal/Ana[C (71.29) 71.27,H (5.46) 5.47,N (10.84) 10.85%]

*anilino-5-(3,4- dimethoxy phenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5e**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.1(2H,s, CH_2), 2.5(3H,s, CH_3), 3.3(6H,s, $OCH_3 \times 2$), 5.9 (1H,s, CH),7.2–7.4 (11H,m, aromatic), 9.8(1H,s, OH), 10.01(IH, s, NH); MS *m/z*: 447(M^+); Cal/Ana[C (67.09) 67.06,H (5.63) 5.62,N (9.39) 9.39%]

*anilino-5-(3, 4, 5- trimethoxy phenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethi-one (**5f**). IR: (KBr) cm*$^{-1}$ 3317(OH), 3220(NH), 1596(C═N), 1320(C—N), 1132 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.0(2H,s, CH_2), 2.8(3H,s, CH_3), 3.5(9H,s, $OCH_3 \times 3$), 5.9 (1H,s, CH), 7.2–7.8 (10H,m, aromatic), 9.2(1H,s, OH), 10.4 (IH, s, NH); MS *m/z*: 478(M^{+1}); Cal/Ana[C (65.39) 65.39,H (5.70) 5.71,N (8.80) 8.80%]

*anilino-5-(4-fluoro phenyl-3-(4-hydroxy-3-methylphe-nyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5g**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S), 824(C—F); *^{1}H–NMR (DMSO-d6) ppm*: 2.0(2H,s, CH_2), 2.6(6H,s, CH_3), 5.3 (1H,s, CH), 7.2–7.8(11H,m, aromatic), 9.9(1H,s, OH), 10.0(IH, s, NH); MS *m/z*: 405(M^+); Cal/Ana[C (68.13) 68.10,H (4.97) 4.98,N (10.36) 10.36%]

*anilino-5-(2-chloro phenyl-3-(4-hydroxy-3-methylphe-nyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5h**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S), 770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.8(3H,s, CH_3), 5.2 (1H,s, CH), 7.2–7.4(11H,m, aromatic), 9.4(1H,s, OH), 10.0(IH, s, NH); MS *m/z*: 421(M^+); Cal/Ana[C (65.47) 65.47,H (4.78) 4.77,N (9.96) 9.96%]

*anilino-5-(2,6-dichloro phenyl-3-(4-hydroxy-3-methyl-phenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5i**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH),1590(C═N), 1320(C—N), 1130 (C═S),770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 1.2 (2H,s, CH_2), 2.5(3H,s, CH_3), 4.6 (1H,s, CH), 7.1–8.4(10H,m, aromatic), 9.8(1H,s, OH), 12.1(IH, s, NH); MS *m/z*: 457(M^{+1}); Cal/Ana[C (60.53) 60.50,H (4.20) 4.21,N (9.21) 9.21%]

*anilino-5-(3-nitro phenyl-3-(4-hydroxy-3-methylphe-nyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**5j**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.1(2H,s, CH_2), 2.4(6H,s, $2 \times CH_3$), 5.3 (1H,s, CH),7.2–7.4(11H,m, aromatic), 8.6(1H,s, OH), 13.5(IH, s, NH); MS *m/z*: 432(M^+); Cal/Ana[C (63.87) 63.86,H (4.66) 4.65,N (12.95)12.94%]

*anilino-5-(furfuryl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methane thione (**5k**). IR: (KBr) cm*$^{-1}$ 3307(OH), 3220(NH), 1590(C═N), 1320(C—N) 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.1(2H,s, CH_2), 2.5(3H,s,CH_3), 5.8 (1H,s, CH), 6.3–7.5(8H,m, aromatic), 7.6–7.7(3H,m, furan), 9.8(1H,s, OH), 9.9(IH, s, NH); MS *m/z*: 378(M^{+1}); Cal/Ana[C (66.82) 66.81,H (5.07) 5.08,N (11.13) 11.12%]

*General method for the preparation of compounds 2-chloroanilino-5- (sub) phenyl -3-(4-hydroxy-3-methylphe -nyl)-4,5-dihydro-1H-1-pyrazolyl methanethiones (**6a–k**)*. To a solution of pyrazolines (0.01moL) (4**a**–**k**) in

ethanol (20mL) was added 2-chloro aryl isothiocyanate (1.66 mL, 0.01 mol) and the reaction mixture was refluxed for 4 h. The reaction mixture was cooled and then poured onto crushed ice, the obtained solid filtered, washed with water and purified from ethanol.

*2-chloroanilino-5- (4-methoxy phenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**6a**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590 (C═N), 1130 (C═S), 1320(C—N); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.5(3H,s, CH_3), 3.3(3H,s, OCH_3), 5.2 (1H,s, CH), 6.5–8.4(11H,m, aromatic), 9.7(1H,s, OH), 10.1(IH, s, NH); MS *m/z*: 451(M^+); Cal/Ana [C (63.78) 63.77,H (4.91) 4.90,N (9.30) 9.32%]

*2-chloroanilino-5- (4-chlorophenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**6b**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590 (C═N), 1320(C—N), 1130 (C═S), 770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 2.3(3H,s, CH_3), 2.8(2H,s, CH_2), 5.0 (1H,s, CH), 7.2–8.0(11H,m, aromatic), 9.9(1H,s, OH), 10.02(IH, s, NH); MS *m/z*: 456(M^+); Cal/Ana [C (60.53) 60.53,H (4.20) 4.20,N (9.21) 9.22%]

*2-chloroanilino-5- (4-dimethylaminophenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**6c**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220 (NH), 1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.0(2H,s, CH_2), 2.5(3H,s, CH_3), 3.1(6H,s, —N $(CH_3)_2$), 5.4 (1H,s, CH), 7.6–8.4(11H,m, aromatic), 9.7(1H,s, OH), 10.0 (IH, s, NH); MS *m/z*: 466(M^{+1}); Cal/Ana[C (64.51) 64.50,H (5.42) 5.41,N (12.05) 12.0%]

*2-chloroanilino-5- phenyl -3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**6d**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590 (C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.3(2H,s, CH_2), 2.7(3H,s, CH_3), 5.24 (1H,s, CH), 6.7–8.1(12H,m, aromatic), 8.7 (1H,s, OH), 9.9 (IH, s, NH);MS *m/z*:421(M^+); Cal/Ana [C (65.47) 65.48,H (4.78) 4.77,N (9.96) 9.97%]

*2-chloroanilino-5- (3,4-dimethoxy phenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl methanethione (**6e**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220 (NH), 1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2),2.5(3H,s, CH_3), 3.3(3H,s, $OCH_3 \times 2$), 4.40 (1H,s, CH), 6.0–8.0(11H,m, aromatic), 9.8(1H,s, OH), 9.9 (IH, s, NH); MS *m/z*: 482(M^{+1}); Cal/Ana[C (62.30) 62.32,H (5.02) 5.02,N (8.72) 8.74%]

*2-chloroanilino-5- (3,4,5-tri methoxy phenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolyl-methanethione (**6f**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220 (NH), 1590(C═N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.5(3H,s, CH_3), 3.6(12H,s, $OCH_3 \times 3$), 5.3 (1H,s, CH), 6.5–7.5 (11H,m, aromatic), 11.3(1H,s, OH), 12.90 (IH, s, NH); MS *m/z*: 511(M^{-1}); Cal/Ana[C (60.99) 60.98, H (5.12) 5.13,N (8.21) 8.22%]

*2-chloroanilino-5-(4-fluorophenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione (**6g**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S), 820(C—F); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2),2.8 (6H,s,CH_3),5.3(1H,s,CH),7.2–7.7 (11H, m, aromatic), 9.5 (1H,s, OH), 10.0 (IH, s, NH): MS *m/z*:439(M^+); Cal/Ana[C (62.75) 62.76,H (4.35) 4.36,N (9.55) 9.53%]

*2-chloroanilino-5-(2-chlorophenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione (**6h**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590 (C═N), 1320(C—N), 1130 (C═S), 770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.8(3H,s, CH_3), 5.6(1H,s,CH), 7.0–8.01(11H,m, aromatic), 10.0(1H,s, OH), 11.10 (1H, s, NH); MS *m/z*: 457 (M^{+1}); Cal/Ana[C (60.53) 60.52,H (4.20) 4.19,N (9.21) 9.20%]

*2-chloroanilino-5-(2,6dichloro phenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione (**6i**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1130 (C═S), 1590(C═N),1320(C—N), 770(C—Cl); *^{1}H–NMR (DMSO-d6) ppm*: 1.3(3H,s,CH_3), 2.5(3H,s, CH_3), 5.7(1H,s,CH), 7.1–7.7 (10H,m, aromatic), 9.7 (1H,s, OH), 11.10 (1H, s, NH); MS *m/z*: 491(M^+); Cal/Ana[C (56.28) 56.28,H (3.70) 3.71,N (8.56) 8.57%]

*2-chloroanilino-5-(3-nitrophenyl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione (**6j**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590 (C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_2), 2.8(6H,s, CH_3), 5.7(1H,s,CH), 7.2–7.9(11H,m, aromatic), 9.7(1H,s, OH), 11. 00 (IH, s, NH); MS *m/z*:466(M^+); Cal/Ana[C (59.16) 59.15,H (4.10) 4.13,N (12.00) 12.02]

*2-chloroanilino-5-furfuryl-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione (**6k**). IR: (KBr) cm $^{-1}$* 3307(OH), 3220(NH), 1590(C═N), 1320(C—N), 1130 (C═S); *^{1}H–NMR (DMSO-d6) ppm*: 2.2(2H,s, CH_3), 2.5(6H,s, CH_3), 6.9–7.6(7H,m, aromatic), 7.8–8.2(3H,s,furan), 9.2(1H,s, OH), 12.0 (IH, s, NH); MS *m/z*: 412(M^{+1});Cal/Ana[C (61.23) 61.12,H (4.40) 4.41,N (10.20) 10.18%]

Biology

The primary screen was conducted using 6.25μg/mL (or molar equivalent of highest molecular weight compound in a series of congeners) against *Mycobacterium tuberculosis H37$_{RV}$* (ATCC27294) in BACTEC

12B medium using the BACTEC 460 radiometric system [10].

Cytotoxicity. All the compounds were tested for cytotoxicity (IC_{50}) in VERO cells at concentrations of 62.5 μg/mL or 10-fold. After 72 h exposure, viability was assessed on the basis of cellular conversion of MTT into a formazan product using the Promega Cell Titer 96 Non-radioactive Cell proliferation method [11].

Result and discussion

Chemistry

N^1-substituted thiocarbamoyl 3-(4′-hydroxy-3′-methyl phenyl)-5-[(substituted) phenyl]−2- pyrazolines (**5a–k**) and (**6a–k**) described in this study are shown in Tables I and II, and a reaction sequence for their preparation is outlined in Scheme I. The chalcones were prepared by reacting 3-methyl-4-hydroxy acetophenone with the appropriate aldehyde in presence of base by a conventional Claisen-Schmidt condensation. Reaction between the synthesized chalcones with hydrazine hydrate in ethanol led to the novel pyrazolines (**4a–k**), which on treatment with various aryl isothiocyanates afforded the respective 1,3,5-trisubstituted pyrazolines (**5a–k**) & (**6a–k**) in 65−92% yield. The purity of the compounds was confirmed by TLC and elemental analyses. Spectral data (^{1}H-NMR and IR) for all the synthesized compounds were in full agreement with the proposed structures.

Antimycobacterial activity

The ring-substituted pyrazoline derivatives (**5a–k**) and (**6a–k**) were tested for their anti-mycobacterial activity *in-vitro* against INH resistant *Mycobacterium tuberculosis* (INHR-MTB) using the BACTEC 460-radiometric system. The results are summarized in Tables I and II with INH, a standard used for comparison. Among the twenty-two newly synthesized compounds, 2-chloroanilino-5-(2,6-dichlorophenyl)-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1*H*-1-pyrazolylmethanethione (**6i**) had the highest potency and exhibited >90% inhibition at MIC 0.96 μg/mL. followed by (**6 g**) and (**6b**) which showed moderate inhibitory activity with MIC 1.00 μg/mL and 1.40 μg/mL, respectively. The 2,6-dichloro group substituted derivative, (**6i**), displayed relatively higher inhibitory activity in general. However the electron withdrawing groups such as, 4-flurophenyl, 2-chlorophenyl, 2,6-dichlorophenyl and 3-nitrophenyl present in the substituted analogue **5 g, 5 h, 5i, 5j, 6 h** and **6j** produced moderate inhibitory activity against (INHR-MTB). On the other hand the analogues with an electron donating group (OCH_3) substituted at the 4′-phenyl (**6a**), 3′,4′- phenyl (**6e**) and 3′,4′,5′- phenyl (**6f**) position showed significantly decreased inhibitory activity. But among the (**5a–k**) derivatives, compounds with 4′-methoxy (**5a**), 3′,4′-

Table I. Physical constants and anti-mycobacterial activity of the synthesized compounds.



5a-k

.

Compound	R_1	Yield (%)	M.P ((°C)	[b](MIC) μg/mL
5a	4-Methoxyphenyl-	63	165	6.25
5b	4-Chlorophenyl-	64	114	1.98
5c	4-Dimethylaminophenyl-	62	85	6.25
5d	Phenyl-	72	125	6.25
5e	3,4-Dimethoxyphenyl-	70	132	6.25
5f	3,4,5-Trimethoxyphenyl-	68	160	6.12
5g	4-Fluorophenyl-	85	105	6.12
5h	2-Chlorophenyl-	70	98	2.76
5i	2,6-Dichlorophenyl-	71	104	2.80
5j	3-Nitrophenyl-	72	99	4.12
5k	Furfuryl-	80	110	2.42
INH	–	–	–	1.86

[a]Recrystalization: Ethanol, Acetic acid; [b]INH-resistant *Mycobacterium tuberculosis*.

Table II. Physical constants and antimycobacterial activity of the synthesized compounds.



6a-k

.

Compound	R_1	Yield(%)	M.P(°C)	[b](MIC) μg/mL
6a	4-Methoxyphenyl-	80	115	6.25
6b	4-Chlorophenyl-	76	164	1.40
6c	4-Dimethylaminophenyl-	92	104	5.89
6d	Phenyl-	70	128	6.15
6e	3,4-Dimethoxyphenyl-	72	148	6.25
6f	3,4,5-Trimethoxyphenyl-	74	85	5.78
6g	4-Fluorophenyl-	74	181	1.00
6h	2-Chlorophenyl-	72	94	3.2
6i	2,6-Dichlorophenyl-	82	116	0.96
6j	3-Nitrophenyl-	84	121	4.76
6k	Furfuryl-	72	195	
INH	–	–	–	1.86

[a]Recrystalization: Ethanol, Acetic acid; [b]INH-resistant *Mycobacterium tuberculosis*.

dimethoxy-(**5e**) and 3′,4′,5′-trimethoxy phenyl substitution (**5f**) exhibited relatively low inhibitory activity against (INHR-MTB). Replacement of phenyl substitution at C-5 with a 2-chlorophenyl group in the pyrazoline analogue improves antitubercular activity. These results clearly showed that the presence of a N-1 2-chlorophenyl substutuent with a dichloro substitution at the C-5 of the pyrazoline (**6a–k**) derivatives, as in **6i**, caused a remarkable improvement in anti-mycobacterial activity.

All the compounds were tested for cytotoxicity (IC_{50}) in a mammalian VERO cells at a concentration



Scheme I. Synthesis of **5a–k** and **6a–k**.

of 62.5μg/mL. After 72 hours exposure, viability was assessed on the basis of cellular conversion of MTT into a formazan product using the Promega Cell Titer 96 Non-radioactive Cell proliferation method. Most of the active compounds were found to be non-toxic at this concentration (62.5μg/mL).

Among the newer derivatives, it is conceivable that derivatives showing anti-mycobacterial activity can be further modified to exhibit better potency than the standard drugs. Further studies to acquire more information about the Structure-Activity Relationships (SAR) within the series are in progress in our laboratory. The pyrazoline derivatives discovered in this study may provide valuable therapeutic intervention for the treatment of tubercular diseases.

Acknowledgements

The author (M.Shahar Yar) wishes to express his thanks to the University Grant Commission – New Delhi, India for the research award and we thank the Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF), National Institute of Allergy and Infections Diseases Southern Research Institute/ GW Long Hansen's Disease Center, Colorado State University Birmingham, Alamba, USA, for the *in vitro* anti-mycobacterial screening and Dr Kiran Smith, National Cancer Institute – USA, for valuable suggestions.

References

[1] Bloom BR, Murray CJL. Tuberculosis: commentary on a re-emergent killer. Science 1992;257:1055.

[2] Barnes PF, Blotch AB, Davidson PT, Snider DE Jr. Tuberculosis in patients with immuno-deficiency virus infection. N Engl J Med 1991;324:1644.

[3] Sbarbaro JA. Multidrug-resistant tuberculosis. It is time to focus on the private sector of medicine. Chest 1997;111:1149.

[4] Fujiwara PI, Cook SV, Rutherford CM, Crawford JT, Glickman SE, Kreiswirth BN, Sachdev PS, Osahan SS, Ebrahimzadeh A, Frieden TR. A continuing survey of drug-resistant tuberculosis. Arch Intern Med 1997;157:531.

[5] Schaberg T, Gloger G, Reichert B, Mauch H, Lode H. Resistant lung tuberculosis in Berlin 1987–1993. Pneumologie 1996;50:21.

[6] Kucukguzel SG, Rollas S. Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents. Farmaco 2002;57:583.

[7] Shaharyar M, Siddiqui AA, Ali MA, Sriram D, Yogeeswari P. Synthesis and *in vitro* antimycobacterial activity of N(1)-nicotinoyl-3-(4′-hydroxy-3′-methyl phenyl)-5-[(sub)phenyl]-2-pyrazolines. Bioorg Med Chem Lett 2006;16:3947–3949.

[8] Nauduri D, Reddy GB. Antibacterials and antimycotics: Part 1: Synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull (Tokyo) 1998;46(8):1254–1260.

[9] Santilli AA, Kim DH, Gregory FJ. Antitubercular activity of substituted 5-oxo-1-thiocarbamoyl-3-pyrazoline-4-alkanoic acid derivatives. J Pharm Sci. 1975;64(6):1057–1058.

[10] Collins L, Frazblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against *Mycobacterium tuberculosis* and *Mycobacterium avium* Antimicrob. Agents Chemother 1997;41:1004.

[11] Gundersen LL, Nissen-Meyer J, Spilsberg B. Synthesis and antimycobacterial activity of 6-arylpurines: The requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 2002;45:1383.